Glecaprevir/Pibrentasvir: First Global Approval
A fixed-dose combination tablet of the hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) glecaprevir and the HCV NS5A inhibitor pibrentasvir [glecaprevir/pibrentasvir; MAVIRET™ (EU); MAVYRET™ (USA)] has been developed by AbbVie. Oral glecaprevir/pibrentasvir 300 mg/120 mg (three 100 mg/40 mg tablets) taken once daily has been approved by the EMA for the treatment of all major genotypes (genotypes 1–6) of chronic HCV infection in adults. It has also been approved by the US FDA for the treatment of adult patients with chronic HCV genotype 1–6 infection without cirrhosis and with compensated cirrhosis, and for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing either an HCV NS5A inhibitor or an NS3/4A PI, but not both. This article summarizes the milestones in the development of glecaprevir/pibrentasvir leading to its first global approval in the EU and subsequent approval in the USA for chronic HCV infection.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Yvette Lamb is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/357AF0607A3E4BD2.
- 1.AbbVie. European Commission grants AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) marketing authorisation for the treatment of chronic hepatitis C in all major genotypes (GT1-6) [media release]. 2017. http://www.abbvie.co.uk/.
- 2.AbbVie Ltd. Maviret (glecaprevir/pibrentasvir) 100 mg/40 mg film-coated tablets: summary of product characteristics. 2017. http://ec.europa.eu/. Accessed 6 Sept 2017.
- 3.AbbVie Inc. MAVYRET™ (glecaprevir and pibrentasvir) tablets, for oral use. 2017. http://www.rxabbvie.com/. Accessed 6 Sept 2017.
- 4.AbbVie. AbbVie recieves U.S. FDA approval of MAVYRET™ (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis C in all major genotypes (GT 1-6) in as short as 8 weeks [media release]. 2017. http://news.abbvie.com/.
- 5.AbbVie. AbbVie’s MAVIRET™ approved by Health Canada for the treatment of chronic hepatitis C in all major genotypes [media release]. 2017. http://www.abbvie.com/.
- 6.AbbVie. Patient medication information: MAVIRET (glecaprevir/pibrentasvir tablets). 2017. http://www.abbvie.ca/. Accessed 6 Sept 2017.
- 7.Enanta Pharmaceuticals. Enanta announces Japanese Ministry of Health, Labour and Welfare grants priority review for AbbVies investigational HCV regimen of glecaprevir/ pibrentasvir (G/P) for the treatment of all major genotypes of chronic hepatitis C [media release]. 2017. http://www.enanta.com/.
- 8.AbbVie. AbbVie receives CHMP positive opinion for MAVIRET™ (glecaprevir/ pibrentasvir) for the treatment of chronic hepatitis C in all major genotypes (GT1-6) [media release]. 2017. http://www.abbvie.com/.
- 9.Enanta Pharmaceuticals. Form 10-Q. 2017. http://ir.enanta.com/. Accessed 6 Sept 2017.
- 11.Lin CW, Liu W, Asatryan A, et al. Steady-state pharmacokinetics and safety of coadministration of pan-genotypic, direct acting protease inhibitor, ABT-493 with pan-genotypic NS5A inhibitor, ABT-530, in healthy adult subjects [abstract no. P0715]. J Hepatol. 2015;62(Suppl. 2):S592.CrossRefGoogle Scholar
- 13.Asselah T, Hezode C, Zadeikis N, et al. ENDURANCE-4: efficacy and safety of ABT-493/ABT-530 treatment in patients with chronic HCV genotype 4, 5, or 6 infection [abstract and poster no. 114]. Hepatology. 2016;64(1 Suppl.):63A.Google Scholar
- 14.Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;. doi:10.1016/S1473-3099(17)30496-6.PubMedGoogle Scholar
- 16.Gane E, Lawitz EJ, Pugatch D, et al. EXPEDITION-IV: safety and efficacy of GLE/PIB in adults with renal impairment and chronic hepatitis C virus genotype 1–6 infection [abstract and poster no. LB-11]. Hepatology. 2016;64(6 Suppl.):1125A.Google Scholar
- 17.Kowdley KV, Colombo M, Zadeikis N, et al. ENDURANCE-2: safety and efficacy of ABT-493/ABT-530 in hepatitis C virus genotype 2-infected patients without cirrhosis, a randomized, double-blind, placebo-controlled study [abstract and poster no. 73]. Hepatology. 2016;64(1 Suppl.):39A.Google Scholar
- 19.Zeuzem S, Feld JJ, Wang S, et al. ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493/ABT-530 in patients with chronic HCV genotype 1 infection [abstract and poster no. 253]. Hepatology. 2016;64(1 Suppl.):132A–3A.Google Scholar
- 29.Hassanein T, Wyles D, Wang S, et al. SURVEYOR-II, part 4: glecaprevir/pibrentasvir demonstrates high SVR rates in patients with HCV genotype 2, 4, 5, or 6 infection without cirrhosis following an 8-week treatment duration [abstract and poster no. LB-15]. In: American Association for the Study of Liver Diseases (AASLD). 2016.Google Scholar